I'll research SYK before writing the preview. Let me start with several parallel queries.Let me read the most recent earnings materials and check for recent news.Let me get the Q1 earnings release numbers, recent stock performance, and any broader recent news.Let me get consensus estimates and recent analyst/news context via web search.# Stryker Corporation (SYK) — Q2 2026 Earnings Preview
This is the "recovery quarter." Q1 was distorted by a late-quarter cyberattack that crippled Stryker's systems for ~3 weeks; management insisted the demand was intact and that most of the lost revenue would be recaptured over the balance of the year. Q2 is the first real test of that thesis — and the stock has already sprinted into the print, raising the bar.
Q1 2026 was an anomaly driven almost entirely by a cyber incident that hit late in the quarter:
| Q1 2026 Metric | Result | Context |
|---|---|---|
| Organic sales growth | +2.4% (US +1.9%, Int'l +3.9%) | Well below SYK's ~8–10% run-rate; cyber-distorted |
| Adjusted EPS | $2.60, down 8.5% YoY | Missed consensus (~$2.98) |
| Reported revenue | $6.02B | Missed (~$6.3B est.) |
| Adjusted gross margin | 63.6%, -190 bps YoY | Lost manufacturing absorption + tariffs |
| Adjusted operating margin | 21.1%, -180 bps YoY | Deleverage on low sales |
Crucially, management framed the shortfall as timing, not demand destruction. The CEO stressed there was "a pause in shipments" — not orders — the capital order book stayed elevated, and Stryker delivered its best-ever Q1 for Mako installations. Full-year guidance was reaffirmed.
The recovery was described in three phases: 1. Orthopaedics revenue-recognition catch-up → concentrated in Q2 (procedures happened; the systems just couldn't book them). 2. Deferred/rescheduled elective procedures → spread across Q2–Q4. 3. Make-to-order MedSurg capital (Endo, Medical — beds, LIFEPAK, defibrillators) → weighted to 2H (Q3/Q4).
| Metric | Consensus | Implied YoY |
|---|---|---|
| Adjusted EPS | ~$3.46–3.49 | +~10.5% |
| Revenue | ~$6.56–6.57B | +~8.9% |
Q2 2025 was a reported ~$6.02B / $2.29 GAAP-diluted quarter, so the Street is modeling a clean reacceleration back to normal Stryker-style growth. Given the phased-recovery guidance, watch whether organic growth snaps back into the high-single/low-double digits — a sub-8% organic print would raise questions about how much revenue was permanently lost vs. merely deferred.
1. Does the full-year guide get raised (or just reaffirmed)? This is the crux. FY26 guidance is 8–9.5% organic sales and $14.90–$15.10 adjusted EPS. CFO Preston Wells explicitly said they'd "take a look… on a full year basis and provide an update" after Q2. A key debate is whether SYK simply absorbed the Q1 hit by removing prior cushion/upside (its historical pattern is to recapture nearly everything). A reaffirm with commentary about "conservatism" reads bullish; a reaffirm with a visibly harder recovery reads bearish. A raise would be a clear positive surprise.
2. Return of segment/product detail. Management withheld line-item detail last quarter because cyber distortions made them un-representative. Q2 should restore full disclosure — and it's the first clean look at the new segment structure: the new Ortho Tech business (Mako + Enabling Tech + Orthopaedic Instruments) within Orthopaedics, and Neuro Cranial folded into Instruments. Expect scrutiny on Knees/Hips (the rev-rec catch-up businesses) and Vascular (Inari).
3. Margins & tariffs. Management reiterated the FY op-margin expansion target (~50 bps this year, within the 150+ bps 3-year framework) but flagged that Q1 and Q2 carry the heaviest tariff headwinds vs. easy 2025 comps (no tariffs in 1H25). They also cited rising input costs (oil/inflation). Watch gross margin recovery off the 63.6% Q1 trough, plus commentary on tariff mitigation. Other guide points: tax rate 15–16%, other income/expense ~$420M for the year (higher interest expense from Inari-related debt).
4. Growth engines / product cadence. - Mako 4 & Mako Shoulder — Shoulder full launch on Mako 4 was slated for mid-year; look for a launch update and utilization commentary. Mako RPS (handheld) early ASC traction. - Pangea (trauma) — just approved in Europe; a multi-year tailwind, but production ramp was slowed by cyber. - LIFEPAK 35 — reramp after production shutdown. - Inari/Vascular — the ~$4.8B acquisition is now ~1.5 years in; watch for confirmation the sales-force "Strykerization" and attrition are behind it.
5. M&A / capital deployment. The Amplitude Vascular Systems (AVS) IVL deal was expected to close in Q2 — look for confirmation and any timeline on FDA filing/approval (potential 2026 revenue). With gross leverage ~2.1x and a strong balance sheet, management signaled it will be active in M&A through year-end. Any cardiovascular platform commentary is a swing factor for the long-term story.
SYK enters the print roughly flat YTD (~$350 vs. ~$348 to start 2026), but the path was volatile: - Gapped down ~6.5% the day after Q1 earnings (Apr 30 ~$315 → May 1 ~$295), bottoming near $282 in mid-May. - Chopped through June on "how real is the recovery" skepticism, with a notable ~6% single-day slide in mid-July on pre-earnings caution. - Then rallied ~13% in the final week into the report (from ~$309 on Jul 22 to ~$350 on Jul 29).
That late-week surge means expectations have firmed up materially. The setup: a company that missed badly last quarter but blamed timing, whose stock has now priced in the recovery. That asymmetry matters — a strong, detail-rich beat with a guidance raise is likely needed to sustain the move, while any hint that the Q1 lost sales aren't fully coming back (or that MedSurg capital recovery is slipping deeper into 2H) could unwind the run quickly.
Net: fundamentals never looked broken — the cyber event was a timing shock. The question July 30 answers is how cleanly Stryker converts an "encouraging demand backdrop" into recaptured revenue, and whether that's already in the price after the pre-earnings rally.
Note: consensus figures are drawn from third-party aggregators (Zacks/Benzinga) and may differ modestly from the number SYK ultimately laps; treat EPS ~$3.46–3.49 and revenue ~$6.56B as approximate.